All In Biotech

Drug Trial Radar · NCT04179409

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3

Actual

Start

Feb 18, 2020

Primary completion

Sep 1, 2021

Study completion Sep 1, 2023

Sponsor

Lead sponsor
Kevin FlaniganAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sarepta Therapeutics, Inc.
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an 48-week open-label study to determine the efficacy and safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Amondys 45Drug

    This drug is used to target skipping of exon 45 of the dystrophin gene.

  • Exondys 51Drug

    This drug is used to target skipping of exon 51 of the dystrophin gene.

  • Vyondys 53Drug

    This drug is used to target skipping of exon 53 of the dystrophin gene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Dystrophin Expression From Baseline Following Treatment With Either AMONDYS 45 (Previously Casimersen), EXONDYS 51 (Previously Eteplirsen ), or VYONDYS 53 (Previously Golodirsen)Time frame: Baseline, 1 year
  2. Monitoring for the Development of Unacceptable Toxicity.Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nationwide Children's Hospital

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.